FCER1G inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   0 News 


«1234»
  • ||||||||||  In vivo programming of myeloid cells by mRNA mediated delivery of novel Fc alpha fusion receptor activates anti-tumor immunity (Section 17) -  Mar 9, 2022 - Abstract #AACR2022AACR_2335;    
    Furthermore, in the B16 syngeneic melanoma model, treatment with the melanoma antigen GP75 targeted Fc-alpha Receptor Fusion Constructs was also associated with the initiation of broad systemic immune responses, characterized by tumoral accumulation of activated CD8+ T cells, reduced tumor associated Tregs and activation of antigen presenting cells in spleen. Together these studies highlight the potential of Fc-alpha Receptor Fusion Construct delivered directly in vivo to program myeloid cells to recognize and kill cancer.
  • ||||||||||  Journal:  Enabling chemical protein (semi)synthesis via reducible solubilizing tags (RSTs). (Pubmed Central) -  Mar 1, 2022   
    Both the protein 2B4 cytoplasmic tail and FCER1G protein have been successfully synthesized via this strategy. Of particular note, the RST strategy could be used for solubilizing the expressed protein segment for protein semi-synthesis of the HMGB1 protein.
  • ||||||||||  Journal, Gene Signature, IO biomarker:  A novel immune-related gene signature predicts survival in esophageal squamous cell carcinoma. (Pubmed Central) -  Feb 5, 2022   
    The novel immune-related prognostic signature we constructed has a good prognostic, predictive ability and can be used as an independent prognostic indicator. Our study provides clinicians with a quantitative tool to predict the probability of individual survival time and helps clinicians select targets for immunotherapies and individualized treatment strategies for ESCC patients.
  • ||||||||||  Journal:  Atlas of genetic effects in human microglia transcriptome across brain regions, aging and disease pathologies. (Pubmed Central) -  Feb 4, 2022   
    Our study provides clinicians with a quantitative tool to predict the probability of individual survival time and helps clinicians select targets for immunotherapies and individualized treatment strategies for ESCC patients. In summary, we have built the most comprehensive catalog to date of genetic effects on the microglia transcriptome and propose molecular mechanisms of action of candidate functional variants in several neurological and neuropsychiatric diseases.
  • ||||||||||  MK-0752 / Merck (MSD), volasertib (BI 6727) / Oncoheroes
    Journal:  PLK1 and NOTCH Positively Correlate in Melanoma and their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways. (Pubmed Central) -  Aug 14, 2021   
    We identified the modulations of several key genes relevant to melanoma progression/metastasis, including MAPK, PI3K, and RAS, as well as some new genes such as Apobec3G, BTK and FCER1G which have not been well-studied in melanoma. In conclusion, our study demonstrated a synergistic anti-proliferative response of a concomitant targeting of PLK1 and NOTCH in melanoma, unraveling a potential novel therapeutic approach for detailed preclinical/clinical evaluation.
  • ||||||||||  [VIRTUAL] Profiling microglial nodules in MS: possible implications for MS lesion formation (Stream 4 Pathogenesis) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1317;    
    In MS tissue, the number of HLA-DR+ nodules was higher compared to stroke tissue (p<0.05). In MS nodules vs MS peri-nodular tissue, 325 differentially expressed (DE) genes were upregulated, involved in immune response (FCGR3A, IRF8, TNFSF13B, CD276, MHC class II, FCER1G), phagocytosis (AXL, CD13, SLC11A1), and nitric oxide metabolism (TLR2, TLR6).
  • ||||||||||  Atlas of genetic effects in human microglia transcriptome across brain regions, aging and disease pathologies (Convention Ctr - 601/603) -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1510;    
    In MS nodules vs MS peri-nodular tissue, 325 differentially expressed (DE) genes were upregulated, involved in immune response (FCGR3A, IRF8, TNFSF13B, CD276, MHC class II, FCER1G), phagocytosis (AXL, CD13, SLC11A1), and nitric oxide metabolism (TLR2, TLR6). In summary, we have built the most comprehensive catalog to date of genetic effects on the microglia transcriptome and propose molecular mechanisms of action of candidate functional variants in several neurological and neuropsychiatric diseases.
  • ||||||||||  Journal:  Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology. (Pubmed Central) -  Jul 30, 2021   
    Single microglia sequencing confirms that Aβ, not TAU, pathology induces marked transcriptional changes in microglia, including increased proportions of activated microglia. We conclude that genetic risk of AD functionally translates into different microglia pathway responses to Aβ pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology.
  • ||||||||||  Clinical, Journal:  Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis. (Pubmed Central) -  Jul 7, 2021   
    The predictive value of the prognostic model including TFF3, EPDR1, MACROD1, ARHGEF12, AMMECR1, NFATC2, HES6, PLEK2 and SNCA was identified, and validated in another external dataset (MMRF-CoMMpass cohort from TCGA). In conclusion, this study provides reliable molecular biomarkers for screening, prognosis, as well as novel therapeutic targets for myeloma LC/SP cells.
  • ||||||||||  Journal:  Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction. (Pubmed Central) -  Apr 29, 2021   
    RESULTS To obtain the pathogenesis associated with both NAFLD and AMI, protein-protein interaction (PPI) network was constructed and the top ten hub genes (TLR2, LILRB2, CXCL1, FPR1, TLR4, TYROBP, MMP9, FCER1G, CLEC4D and CCR2) were selected with CONCLUSIONS The results of this study suggesting some novel genes may play an important role in the occurrence and progression NAFLD and AMI. But more experimental researches and clinical trials need to verify.